Standard Biotools (LAB) EBITDA (2010 - 2026)

Standard Biotools (LAB) has 17 years of EBITDA data on file, last reported at -$12.5 million in Q1 2026.

• On a quarterly basis, EBITDA rose 53.67% year-over-year to -$12.5 million in Q1 2026; TTM through Mar 2026 was -$95.8 million, a 12.94% increase from a year earlier, with the FY2025 full-year figure at -$110.2 million, up 13.52% from the prior year.
• EBITDA for Q1 2026 stood at -$12.5 million, up from -$24.6 million in the prior quarter.
• Over the last five years, EBITDA for LAB reached as high as -$12.5 million in Q1 2026 and fell as low as -$60.2 million in Q1 2024.
• Historically, EBITDA has averaged -$27.0 million across 5 years, with a median of -$26.1 million in 2024.
• Across the five-year window, EBITDA plunged 262.7% in 2024 and soared 55.19% in 2025, its largest moves.
• Year by year, EBITDA stood at -$21.1 million in 2022, then declined by 1.3% to -$21.4 million in 2023, then fell by 21.96% to -$26.1 million in 2024, then grew by 5.51% to -$24.6 million in 2025, then surged by 49.29% to -$12.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$12.5 million in Q1 2026, -$24.6 million in Q4 2025, and -$32.9 million in Q3 2025.